金宇生物技术股份有限公司修订拟回购注销2023年员工持股计划部分股票数量公告
核心要点摘要
- 金宇生物于2026年4月22日召开董事会，通过了关于回购注销2023年员工持股计划部分股票的议案。
- 由于员工持股计划第三个解锁期业绩考核未达成及部分员工离职，拟回购注销的股票数量由906.89万股修订为851.84万股。
- 同时，公司计划注销回购专用证券账户中使用期限满三年的回购股份330.16万股。
- 注销完成后，公司注册资本将由人民币1,111,747,826元变更为1,099,927,826元，股份总数相应减少。
- 本次注销事项尚需提交股东大会审议，最终以中国证券登记结算公司出具的变更登记表为准。
详细解读
金宇生物技术股份有限公司（证券代码：600201，证券简称：生物股份）于2026年4月22日召开第十二届董事会第五次会议，审议通过了《关于拟回购注销2023年员工持股计划部分股票及注销回购专用证券账户中部分股票的议案》及《公司章程及其他制度的修订议案》。
此前公告显示，公司拟回购注销2023年员工持股计划已授予但尚未解锁的权益份额对应的股票数量为906.89万股，并拟注销回购专用证券账户中使用期限满三年的回购股份330.16万股。然而，经过人员变动核查后，公司修订了拟回购注销数量：拟回购注销的员工持股计划股票由906.89万股调整为851.84万股，总注销股票数由1,237.05万股修订为1,182万股。
导致本次回购注销的主要原因是2023年员工持股计划首次授予部分第三个解锁期的公司层面业绩考核未达成，以及11名持有人因个人原因离职，不再具备员工持股计划持有人资格。因此，未解锁的权益份额不得解锁，相应的851.84万股予以回购注销，回购价格为6.23元/股。
注销完成后，公司股本结构将发生变动：股份总数将由1,111,747,826股减少至1,099,927,826股，注册资本由人民币1,111,747,826元变更为1,099,927,826元。相关条款也将体现在公司章程的修订中。
值得关注的是，该次注销与章程修订事项尚需提交股东大会审议，最终以中国证券登记结算公司出具的证券变更登记表为准。
对投资者的影响与注意事项
- 股份数量减少，或将影响每股收益及每股资产等财务指标。
- 员工持股计划业绩未达标及人员流动，反映公司业务阶段性压力及管理调整。
- 回购注销价格为6.23元/股，投资者可关注公司后续股价表现。
- 最终结果尚需股东大会批准，存在一定不确定性。
结论
此次公告涉及股份回购注销与公司章程修订，属于公司资本结构重大调整，可能对公司股价产生影响，投资者应密切关注后续进展及股东大会决议。
免责声明
本文仅为信息披露与分析，不构成任何投资建议。投资者应结合自身情况及专业意见作出决策。
Jinyu Bio-Technology Co., Ltd.: Revised Announcement on the Repurchase and Cancellation of Certain Shares from the 2023 Employee Stock Ownership Plan
Key Points Summary
- On April 22, 2026, Jinyu Bio held a board meeting and approved the proposal to repurchase and cancel certain shares from the 2023 Employee Stock Ownership Plan (ESOP).
- Due to unfulfilled performance targets in the third unlocking period and employee departures, the number of shares to be repurchased and cancelled was revised from 9.0689 million to 8.5184 million shares.
- Additionally, the company plans to cancel 3.3016 million repurchased shares that have been held for more than three years in the special repurchase account.
- After cancellation, the company’s registered capital will decrease from RMB 1,111,747,826 to RMB 1,099,927,826, with the total number of shares reduced accordingly.
- This cancellation is subject to shareholder approval, and the final change will be confirmed by the China Securities Depository and Clearing Corporation.
Detailed Analysis
Jinyu Bio-Technology Co., Ltd. (Stock Code: 600201) held its twelfth board meeting on April 22, 2026, approving the proposals to repurchase and cancel certain shares from the 2023 ESOP, and to amend the company’s articles and other regulations.
Previously, the company planned to repurchase and cancel 9.0689 million shares from the ESOP and 3.3016 million shares held for three years in the repurchase account, totaling 12.3705 million shares. After personnel review, the repurchase and cancellation number was revised to 8.5184 million ESOP shares and a total of 11.82 million shares.
The main reason for this repurchase and cancellation is the failure to meet company-level performance targets in the third unlocking period of the ESOP, as well as 11 holders leaving the company and losing eligibility. As a result, 8.5184 million shares will be repurchased and cancelled at a price of RMB 6.23 per share.
Once completed, the company’s share capital structure will change: the total number of shares will decrease from 1,111,747,826 to 1,099,927,826, and the registered capital will change accordingly. These changes will also be reflected in amendments to the articles of association.
Note, this action is pending shareholder approval, and the final numbers will be confirmed by the securities registration authority.
Implications for Investors
- Reduction in share count may impact per-share financial metrics.
- Failure to meet ESOP targets and employee turnover reflects business and management challenges.
- Repurchase price is RMB 6.23/share; investors should monitor subsequent share price movements.
- Final outcome depends on shareholder approval, introducing uncertainty.
Conclusion
This announcement involves significant adjustments to company capital structure, which could affect the share price. Investors should closely watch further developments and shareholder meeting outcomes.
Disclaimer
This article is for information and analysis only and does not constitute investment advice. Investors should make decisions based on their own circumstances and professional guidance.
